Hephaistos-Pharma
Develops innate immune therapies for cancer, including myeloid-rich tumors resistant to immunotherapy
Highlights
- Hiring1 open role
- New on EvolcAdded 2026-11-13
About Hephaistos-Pharma
Hephaistos Pharma is a biopharmaceutical company developing TLR4 agonists to stimulate innate immunity and make myeloid-rich tumors responsive to immunotherapy. Its lead candidate, HEPHA440, has been studied in preclinical cancer models and is scheduled to enter clinical trials in 2028.
The company is based in Orsay, France, and was founded in 2018. It is hiring a Preclinical Development Manager.
Product: Develops TLR4 agonist drug candidates for cancer immunotherapy, including HEPHA440.
Jobs at Hephaistos-Pharma (1)
Hephaistos-Pharma is hiring for one role.
Preclinical Development Manager
New on Evolc
More biotech & pharma companies
Holopharm
Pharmaceutical contract laboratory providing analysis, formulation and production services for industrial clientsNew on EvolcHome Biosciences
Biotech venture builder that created European life sciences companies addressing unmet medical needsNew on EvolcHorus Pharma
French ophthalmology pharmaceutical lab offering eye-health drugs and services to eye-care professionals and patientsHuman Cell Design
Human beta cell models and preclinical CRO services for pharma diabetes and obesity drug researchNew on EvolcHumana Biosciences
Preclinical contract research and experimental models for pharmaceutical, nutraceutical and plant-extract developersNew on EvolcHuntx Pharma
Develops small-molecule therapies for Huntington’s disease and other neurological disorders linked to axonal transport defectsYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- LiteSpeedHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.